Adjuvants influence the maturation of VRC01-like antibodies during immunization

Summary: Once naive B cells expressing germline VRC01-class B cell receptors become activated by germline-targeting immunogens, they enter germinal centers and undergo affinity maturation. Booster immunizations with heterologous Envs are required for the full maturation of VRC01-class antibodies. He...

Full description

Bibliographic Details
Published in:	iScience
Main Authors:	Maria L. Knudsen, Parul Agrawal, Anna MacCamy, K. Rachael Parks, Matthew D. Gray, Brittany N. Takushi, Arineh Khechaduri, Kelsey R. Salladay, Rhea N. Coler, Celia C. LaBranche, David Montefiori, Leonidas Stamatatos
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Subjects:	Biological sciences Immune response Immunology Virology
Online Access:	http://www.sciencedirect.com/science/article/pii/S258900422201745X

Similar Items

Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.
by: Parul Agrawal, et al.
Published: (2025-05-01)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
by: Emilie Seydoux, et al.
Published: (2021-05-01)

Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope
by: Andrew Wilcox-King, et al.
Published: (2025-08-01)

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
by: Myra Happe, et al.
Published: (2025-02-01)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern
by: Melissa García-Vega, et al.
Published: (2023-04-01)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01)

Reduced anti-viral IgG repertoire in HIV-exposed but uninfected infants compared to HIV-unexposed infants
by: Rachael Gachogo, et al.
Published: (2024-07-01)

Editorial: New approaches toward understanding challenges in molecular virology: computational techniques and machine learning
by: Srirupa Chakraborty, et al.
Published: (2024-09-01)

Mechanisms and efficacy of small molecule latency-promoting agents to inhibit HIV reactivation ex vivo
by: Julie Janssens, et al.
Published: (2024-10-01)

Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
by: Maria P. Lemos, et al.
Published: (2024-11-01)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
by: E. Fabian Cardozo-Ojeda, et al.
Published: (2021-08-01)

33rd Brazilian Society for Virology (SBV) 2022 Annual Meeting
by: Maite Freitas Silva Vaslin, et al.
Published: (2023-04-01)

The 32nd Brazilian Society of Virology (SBV) 2021 Annual Meeting
by: Maite Freitas Silva Vaslin, et al.
Published: (2022-03-01)

Influenza A virus propagation requires the activation of the unfolded protein response and the accumulation of insoluble protein aggregates
by: Mariana Marques, et al.
Published: (2024-03-01)

On-site detection and differentiation of African swine fever virus variants using an orthogonal CRISPR-Cas12b/Cas13a-based assay
by: Zhe Wang, et al.
Published: (2024-04-01)

A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates
by: Lingyan Cui, et al.
Published: (2024-07-01)

Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination
by: Virginia M. Stone, et al.
Published: (2022-10-01)

Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
by: Praveen Neeli, et al.
Published: (2023-07-01)

Calcium mobilization is responsible for Thapsigargin induced Epstein Barr virus lytic reactivation in in vitro immortalized lymphoblastoid cell lines
by: Aki Hoji, et al.
Published: (2018-11-01)

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
by: Pai Peng, et al.
Published: (2022-11-01)

CDKL5 regulates p62-mediated selective autophagy and confers protection against neurotropic viruses
by: Josephine W. Thinwa, et al.
Published: (2024-01-01)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
by: Yunda Huang, et al.
Published: (2023-11-01)

Loss of West Nile virus genetic diversity during mosquito infection due to species-dependent population bottlenecks
by: Emily A. Fitzmeyer, et al.
Published: (2023-10-01)

Virus genes and host correlates of pathology are markedly reduced during respiratory syncytial and influenza virus co-infection in BALB/c mice
by: Olaitan T. Ayegbusi, et al.
Published: (2019-01-01)

The Southern African Society for Virology
by: Wolfgang Preiser, et al.
Published: (2024-08-01)

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency
by: Nicole Frumento, et al.
Published: (2022-08-01)

HIV reservoir quantification using cross-subtype multiplex ddPCR
by: Noah A.J. Cassidy, et al.
Published: (2022-01-01)

Mucosal boosting increases protective efficacy of an influenza vaccine in mice
by: Liping Wang, et al.
Published: (2025-06-01)

Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load
by: Cynthia L. Swan, et al.
Published: (2023-10-01)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
by: Jeong Hyun Lee, et al.
Published: (2021-09-01)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
by: Guo D, et al.
Published: (2012-09-01)

Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
by: Sirle Saul, et al.
Published: (2023-10-01)

Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD
by: Yaozong Chen, et al.
Published: (2023-01-01)

First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody
by: Denis R. Beckford-Vera, et al.
Published: (2022-03-01)

Report from the 9th Italian Society for Virology (SIV-ISV) 2025 Annual Meeting
by: Anna De Filippis, et al.
Published: (2026-06-01)